Biohaven Pharmaceuticals, Inc.
Clinical trials sponsored by Biohaven Pharmaceuticals, Inc., explained in plain language.
A biopharmaceutical company focused on neuroscience and immunology.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Hope for ataxia: experimental drug shows promise in Late-Stage trial
Disease control CompletedThis study tested a drug called troriluzole in 141 adults with spinocerebellar ataxia, a rare disease that affects balance and coordination. Participants took either the drug or a placebo daily for 8 weeks. The main goal was to see if troriluzole could improve symptoms like walki…
Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
OCD drug candidate troriluzole fails to beat placebo in large trial
Symptom relief CompletedThis Phase 3 trial tested whether adding troriluzole to standard OCD medications could reduce symptoms better than a placebo. The study enrolled 589 adults with OCD who had not responded well enough to their current treatment. After 8 weeks, troriluzole did not lead to significan…
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New drug troriluzole tested for OCD patients not helped by antidepressants
Symptom relief CompletedThis completed Phase 2/3 trial tested whether adding troriluzole to standard antidepressant treatment can reduce OCD symptoms. 426 adults with moderate-to-severe OCD who had not responded well enough to their current medication took either troriluzole or a placebo for 12 weeks. T…
Phase: PHASE2, PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Could this pill help when OCD meds fall short?
Symptom relief CompletedThis study tested whether adding troriluzole to standard OCD treatment works better than a placebo. It involved 456 adults with OCD who hadn't fully responded to their current medication. The main goal was to see if troriluzole could further reduce OCD symptoms and improve daily …
Phase: PHASE3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC